Gland Pharma Q2 FY27 Profit Jumps 58% as CDMO Grows 31%
Gland Pharma Q2 FY27 net profit rises 58% to ₹291 crore as revenue grows 23% to ₹1,834 crore, led by 31% CDMO growth and a 42% jump in US sales.
Gland Pharma Q2 FY27 net profit rises 58% to ₹291 crore as revenue grows 23% to ₹1,834 crore, led by 31% CDMO growth and a 42% jump in US sales.
Gland Pharma wins USFDA approval for generic Methylprednisolone Acetate Injectable Suspension, equal to Pfizer’s Depo-Medrol, a USD 214 million US market.
Ahmedabad-based fermentation API maker Concord Biotech grew Q2 FY27 revenue 25% to ₹309.1 crore as API sales rose 30%, while solvent and power costs trimmed gross margin; the company added two US ANDA approvals, launched its Inspira dermatology division and is chasing injectables contracts.
Dr Reddys Laboratories and US-based Gland Pharma have collaborated to market and distribute a diverse portfolio of eight injectable Abbreviated […]